PIPELINE

Telomere Therapeutics aims to maximize the potential of telomere elongation in different diseases

PRODUCT

INDICATION

DISCOVERY

PRECLINICAL PoC

IND - ENABLING

CLINICAL

AAV-TERT-01

IPF

DISCOVERY

PRECLINICAL PoC

IND - ENABLING

CLINICAL

AAV-TERT-02

Undisclosed

DISCOVERY

PRECLINICAL PoC

IND - ENABLING

CLINICAL

AAV-TERT-03

Undisclosed

DISCOVERY

PRECLINICAL PoC

IND - ENABLING

CLINICAL

AAV-TERT-04

Undisclosed

DISCOVERY

PRECLINICAL PoC

IND - ENABLING

CLINICAL

Our lead program is an AAV-based therapy primarily focused on idiopathic pulmonary fibrosis (IPF), a disease with very poor prognosis and a high mortality rate.

Telomere-Therapeutics-privacy-policy

Idiopathic Pulmonary Fibrosis

One of the most common and deadly interstitial lung disease.

Unfortunately, there is currently no cure for iPF, although certain medicines may slow the progression of disease.

Primarily occurs in adults.

Lung transplant is the standard of care, yet applicable to less than 5% of patients with severe iPF.

The molecular cause of disease is unknown (idiopathic).

The bottom line: median survival of <5 years after diagnosis.